Donna Cryer joins Jörn Schattenberg, Louise Campbell and Roger Green for an impactful episode which weighs the complexities of competing needs across all Fatty Liver stakeholders. The session expands discourse on the recently discussed ICER draft report to consider the developing nomenclature consensus and other impending decisions. Critically, the group grapples with challenges associated with honoring the precedence of patient-centricity.
Donna opens this conversation with several calls to action for patient advocacy in the NASH community. Her first recommendation is to recruit different disciplines to administer and evaluate an impact report regarding nomenclature consensus. Next, and more broadly, she asks all stakeholders to consider how to genuinely and effectively build an inclusive advocacy community. Roger asks Jörn what he believes to be realistic that the field can do for these aims today. First, Jörn notes that many different societies can agree on what is considered to be a severe patient and what an unfavorable outcome is in terms of liver disease. He goes on to say that with therapies in the pipeline and tests like FIB-4 available and widely implementable now, we have indeed come a long way as a field. The risks he perceives surrounding initiatives such as the ICER draft report and nomenclature consensus revolve around slowing, detouring or otherwise dismantling the tremendous progress that has been made. As the session wraps up, Donna offers her thoughts on where this is all heading.
Listen to the full feature to engage with these impactful moments. If you enjoy the episode, have questions or interest around endocrinology and Fatty Liver disease, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.
Stay Safe and Surf On!